Novo Nordisk's oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study (58.20 +1.00)
- Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy) achieved significant weight loss, with one in three study participants losing 20% or more body weight.
- Oral semaglutide 25 mg also demonstrated improvements in the ability to perform everyday physical activities such as bending, standing, walking, being physically active, and improvements in cardiovascular risk factors.
- Oral semaglutide 25 mg is the first oral GLP-1 therapy submitted to the US Food and Drug Administration for chronic weight management,2 and Novo Nordisk has already begun production at its US sites.